Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FHCZ2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,949
Award facts
- Contract value 100% obligated
- $34,948.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $34,948.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. The delivery order, issued on January 2, 2026, with an ultimate completion date of January 26, 2026, carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was established on November 13, 2025, with a ceiling value of $499.9 million through December 31, 2036.
DMS Pharmaceutical Group serves as a critical regional pharmaceutical supplier within the broader $30.3 billion PPV-G GEN V acquisition strategy, which authorizes firm fixed-price delivery orders for diverse pharmaceutical products and medical consumables to support Department of Defense military healthcare facilities worldwide. The company's established performance on numerous prior delivery orders demonstrates its operational capacity to fulfill specialized pharmaceutical requirements across the federal military medical system. Xolair, an immunosuppressant biologic agent, represents one component of the company's comprehensive product portfolio, which includes oncology treatments, vaccines, emergency medications, and routine pharmaceuticals distributed to support DoD healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FHCZ2?
SPE2DR26FHCZ2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 2, 2026.
How much is contract SPE2DR26FHCZ2 worth?
The government has obligated $34,949 on SPE2DR26FHCZ2.
Is contract SPE2DR26FHCZ2 an order under another contract?
Yes. SPE2DR26FHCZ2 is a delivery order under SPE2DR25D9207, an indefinite delivery contract.
Was contract SPE2DR26FHCZ2 competed?
The extent of competition for SPE2DR26FHCZ2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award